Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Investigating the Effectiveness of Brexpiprazole in Schizophrenic Patients with Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Study

Stefania Chiappini
ORCID logo ,
Clara Cavallotto
* ORCID logo ,
Alessio Mosca
ORCID logo ,
Francesco Di carlo
ORCID logo ,
Tommaso Piro
,
Chiara Lorenzini
,
Maria pia Di paolo
,
Maria Pepe
,
Marco Di nicola
ORCID logo ,
Valerio Ricci
ORCID logo ,
Mauro Pettorruso
,
Giovanni Martinotti
ORCID logo
Version 1 : Received: 17 January 2024 / Approved: 18 January 2024 / Online: 18 January 2024 (14:03:17 CET)

How to cite: Chiappini, S.; Cavallotto, C.; Mosca, A.; Di carlo, F.; Piro, T.; Lorenzini, C.; Di paolo, M.P.; Pepe, M.; Di nicola, M.; Ricci, V.; Pettorruso, M.; Martinotti, G. Investigating the Effectiveness of Brexpiprazole in Schizophrenic Patients with Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Study. Preprints 2024, 2024011404. https://doi.org/10.20944/preprints202401.1404.v1 Chiappini, S.; Cavallotto, C.; Mosca, A.; Di carlo, F.; Piro, T.; Lorenzini, C.; Di paolo, M.P.; Pepe, M.; Di nicola, M.; Ricci, V.; Pettorruso, M.; Martinotti, G. Investigating the Effectiveness of Brexpiprazole in Schizophrenic Patients with Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Study. Preprints 2024, 2024011404. https://doi.org/10.20944/preprints202401.1404.v1

Abstract

Background: Dual disorders (DD) involve the coexistence of substance use disorder (SUD) with another mental illness, often from psychotic and affective categories. This study explores the ef-fectiveness of brexpiprazole, a third-generation antipsychotic, in individuals diagnosed with schizophrenia spectrum disorder (DSM-V) and comorbid AUD/SUD (DSM-V). Methods: Eighteen enrolled patients underwent psychometric assessments at baseline and one month into brexpiprazole treatment administered at a mean dosage of 2 mg/day. Results: Brexpiprazole demonstrated significant reductions in psychopathological burden (PANSS total score, p=0.004), improved CGI total score (p=0.042), and decreased MOAS total score (p=0.012). Quality of life improved in SF-36 subscales (p<0.05). Substance craving reduction, though observed, did not reach statistical significance. Conclusions: This study provides initial evidence supporting brexpiprazole's efficacy and safety with positive effects on psychopathology and quality of life, emphasizing the need for tailored, comprehensive treatment strategies in this complex patient population.

Keywords

dual disorders; substance use disorder; brexpiprazole; real-world study; addiction; substance-induce-psychosis.

Subject

Medicine and Pharmacology, Psychiatry and Mental Health

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.